^
Association details:
| Biomarker: | MUC4 underexpression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | gemcitabine (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine
Published date:
02/15/2017
Excerpt:
Low expression of MUC4 was associated with favorable survival (p = .027), whereas high MUC4 expression did not correlate with survival (p = .87) in patients receiving adjuvant gemcitabine treatment.
DOI:
https://doi.org/10.1080/00365521.2017.1290134
